Internetiühendust pole — kuvatakse lehe salvestatud versioon.

Equillium Inc

USUSD
← Aktsiafiltri juurde
US:EQLSE:0A4D

Equillium Inc (US:EQ) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 2. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.

Ettevõtte kohta

Veebileht
equilliumbio.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Peakontor
LA JOLLA, United States
Tegevjuht
Bruce Steel
Töötajad
14
Ringluses olevad aktsiad
63.41 mln seisuga 2026-08-07
Vabalt kaubeldavad aktsiad
36.97 mln
Turukapitalisatsioon
89.41 mln USD
Siseringi isikud
16%
Institutsionaalsed investorid
65.76%
Tegevusala (SIC)
Pharmaceutical Preparations
FCF
−20.1 mln USD
Võlg
7.64 mln USD
netoraha
Kasum ja FCF — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
Kirjeldus

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Börsid ja tikkerid

BörsTikkerValuutaHindTüüp
US USA StocksEQ põhinoteeringUSD1.44 +3.60%tavalised aktsiad
LSE London Stock Exchange0A4D IOBUSD1.4 +0.00%tavalised aktsiad

Hind 3 kuu jooksul

3M1Y3Y5Y
tõususepäev langusepäevViige kursor / puudutage päeva — avamis-, sulgemis-, kõrgeim ja madalaim hind

Selle nädala uudised

Pressiteated ettevõtte investorite veebisaidilt, uuendatakse iga päev. Lingid viivad ettevõtte veebilehele. Pealkirjad on originaalkeeles, nagu ettevõtte veebilehel.

06.10.2026Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
05.10.2026Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
reklaam

Suurimad omanikud

OmanikOsalusAktsiadAruande kuupäev
Jupiter Topco LLC10.24%6.49 mln2026-06-30
Decheng Capital LLC7.01%4.45 mln2026-06-30
Affinity Asset Advisors,…6.47%4.1 mln2026-06-30
Adar1 Capital Management…5.93%3.76 mln2026-06-30
Aberdeen Group plc5.73%3.63 mln2026-06-30
abrdn Life Sciences Inve…5.73%3.63 mln2026-06-30
Woodline Partners LP5.52%3.5 mln2026-06-30
RA Capital Management, L…4.88%3.1 mln2026-06-30
Stempoint Capital LP3.18%2.02 mln2026-06-30
Vanguard Capital Managem…2.87%1.82 mln2026-06-30
Eversept Partners, LP2.4%1.52 mln2026-06-30
VANGUARD INDEX FUNDS-Van…2.21%1.4 mln2026-06-30
CONNELLY STEPHEN (Presid…≈1.2%762 0252026-06-05
VANGUARD INDEX FUNDS-Van…0.54%344 4892026-06-30
Fidelity Concord Street…0.26%162 8512026-07-31
iShares Trust-iShares Mi…0.24%153 0762026-08-31
American Century ETF Tru…0.12%75 4112026-08-31
ZEDELMAYER CHRISTINE (Ch…≈0.1%62 5862026-06-05
Fidelity Concord Street…0.09%54 6772026-07-31
Fidelity Concord Street…0.07%47 4652026-07-31
Invesco Exch-Trd Fd. TRT…0.06%38 5162026-08-31
Fidelity Concord Street…0.06%36 6832026-07-31
TOM PENNY (Officer)—02026-05-28
KEYES JASON A (Chief Fin…——2025-01-23